Hematopoietic Stem Cell Transplantation in Thalassemia

Area of Science:

• Hematology
• Transplantation Immunology
• Genetic Blood Disorders

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is the sole potentially curative treatment for transfusion-dependent thalassemia major.
• Recent advancements have focused on reducing conditioning regimen toxicity and graft-versus-host disease (GVHD) incidence.
• Expanded donor options, including unrelated, haploidentical, and umbilical cord blood, increase HSCT feasibility for patients without HLA-identical siblings.

Purpose of the Study:

• To provide a comprehensive overview of allogeneic HSCT for thalassemia.
• To reassess the current clinical outcomes of HSCT in thalassemia patients.
• To discuss future directions and perspectives in the field.

Main Methods:

• Review of current literature and clinical data on allogeneic HSCT for thalassemia.
• Analysis of outcomes, including survival rates, GVHD incidence, and quality of life.
• Evaluation of the impact of novel conditioning regimens and alternative stem cell sources.

Main Results:

• Allo-HSCT has demonstrated significant improvements in patient outcomes and quality of life.
• Reduced toxicity of conditioning regimens and lower GVHD rates have been achieved.
• Increased availability of alternative stem cell sources broadens HSCT eligibility.

Conclusions:

• Allogeneic HSCT remains a cornerstone therapy for thalassemia major.
• Ongoing research and technological advancements continue to enhance HSCT efficacy and safety.
• Future perspectives involve further optimizing HSCT protocols and expanding patient access.